Advertisement





Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2001; 37:1910-1915
© 2001 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Freedberg, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freedberg, N. A.

CLINICAL STUDY: ELECTROPHYSIOLOGY

Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy

Implications for antiarrhythmic therapy and driving restrictions

Nahum A. Freedberg, MDa,b, John N. Hill, MDa, Richard I. Fogel, MD, FACCa, Eric N. Prystowsky, MD, FACCa the CARE Group

a The Care Group, Indianapolis, Indiana, USA
b Nahum A. Freedberg’s current address: Cardiology Department, Ha’Emek Medical Center, Afula 18101, Israel

Manuscript received June 5, 2000; revised manuscript received January 23, 2001, accepted February 6, 2001.

Reprint requests and correspondence: Dr. Eric N. Prystowsky, The Care Group, 8333 Naab Road, Suite 200, Indianapolis, Indiana 46260
eprystow{at}thecaregroup.com

OBJECTIVES

The purpose of this study was to investigate whether clinical or electrophysiologic characteristics could predict initial and subsequent implantable cardioverter defibrillator (ICD) therapy.

BACKGROUND

Identification of markers to predict subsequent ICD therapy and symptoms after the first event could affect patient management.

METHODS

We analyzed baseline and follow-up data on 125 ICD patients followed for 408 ± 321 days. Medications and ICD programming were not changed after first ICD therapy.

RESULTS

Implantable cardioverter defibrillator therapy occurred in 58 patients (46%). Clinical features were as follows: mean left ventricular ejection fraction (LVEF) 29% ± 15%; coronary artery disease 84%; presenting arrhythmia with sustained monomorphic ventricular tachycardia (SMVT) in 68%. In a multivariate analysis the relative risk for ICD therapy in patients presenting with SMVT versus cardiac arrest (CA) was 2.57 (range, 1.32 to 5.01), and for patients with LVEF ≤25%, 1.95 (1.11 to 3.45), respectively (p < 0.05). Implantable cardioverter defibrillator therapy was not predicted by any other variable. Forty-six patients had second ICD therapy. Mean time to second ICD therapy was only 66 ± 93 days compared with 138 ± 168 days for first ICD therapy (p < 0.05). No predictor for second ICD therapy was found. Regarding symptoms, impaired consciousness during initial ICD therapy was predicted only by SMVT cycle length <250 ms at electrophysiologic testing. In contrast, symptoms were similar between first and second ICD therapy (p = 0.0001). Of note, ventricular tachycardia cycle length preceding first and second ICD therapy was similar (r = 0.76, p = 0.001).

CONCLUSIONS

First ICD therapy tends to occur in patients presenting with SMVT and LVEF ≤25%. Subsequent therapy occurs sooner and is unpredictable, suggesting that antiarrhythmic drug therapy should be considered after the first symptomatic ICD therapy. Symptoms during first ICD therapy predict subsequent symptoms, and patients presenting with SMVT and asymptomatic first ICD therapy are at very low risk for future syncopal ICD therapy.

Abbreviations and Acronyms
  AAD = antiarrhythmic drug
  AF = atrial fibrillation
  CA = cardiac arrest
  EPS = electrophysiologic study
  ICD = implantable cardioverter defibrillator
  LVEF = left ventricular ejection fraction
  SMVT = sustained monomorphic ventricular tachycardia
  VT = ventricular tachycardia




This article has been cited by other articles:


Home page
Eur Heart JHome page
C. J. W. Borleffs, L. van Erven, M. Schotman, E. Boersma, P. Kies, A. E. B. van der Burg, K. Zeppenfeld, M. Bootsma, E. E. van der Wall, J. J. Bax, et al.
Recurrence of ventricular arrhythmias in ischaemic secondary prevention implantable cardioverter defibrillator recipients: long-term follow-up of the Leiden out-of-hospital cardiac arrest study (LOHCAT)
Eur. Heart J., July 1, 2009; 30(13): 1621 - 1626.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
Task force members, J. Vijgen, G. Botto, J. Camm, C.-J. Hoijer, W. Jung, J.-Y. Le Heuzey, A. Lubinski, T. M. Norekval, M. Santomauro, et al.
Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators
Europace, June 13, 2009; (2009) eup112v1.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. H. Schoenfeld
Contemporary Pacemaker and Defibrillator Device Therapy: Challenges Confronting the General Cardiologist
Circulation, February 6, 2007; 115(5): 638 - 653.
[Full Text] [PDF]


Home page
EuropaceHome page
G. Klein, C. Lissel, A.-C. Fuchs, A. Gardiwal, H. Oswald, M. deSousa, A. M. Pichlmaier, R. Lichtinghagen, H. Geerlings, P. Lippolt, et al.
Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.
Europace, August 1, 2006; 8(8): 618 - 624.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A Verma, F Kilicaslan, D O Martin, S Minor, R Starling, N F Marrouche, S Almahammed, O M Wazni, S Duggal, R Zuzek, et al.
Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies
Heart, February 1, 2006; 92(2): 190 - 195.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. Whang, M. A. Mittleman, D. Q. Rich, P. J. Wang, J. N. Ruskin, G. H. Tofler, J. E. Muller, C. M. Albert, and for the TOVA Investigators
Heart Failure and the Risk of Shocks in Patients With Implantable Cardioverter Defibrillators: Results From the Triggers Of Ventricular Arrhythmias (TOVA) Study
Circulation, March 23, 2004; 109(11): 1386 - 1391.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
A. E. Buxton
The Clinical Use of Implantable Cardioverter Defibrillators: Where Are We Now? Where Should We Go?
Ann Intern Med, March 18, 2003; 138(6): 512 - 514.
[Full Text] [PDF]


Home page
CirculationHome page
A. E. Buxton, K. L. Lee, G. E. Hafley, D. G. Wyse, J. D. Fisher, M. H. Lehmann, L. A. Pires, M. R. Gold, D. L. Packer, M. E. Josephson, et al.
Relation of Ejection Fraction and Inducible Ventricular Tachycardia to Mode of Death in Patients With Coronary Artery Disease: An Analysis of Patients Enrolled in the Multicenter Unsustained Tachycardia Trial
Circulation, November 5, 2002; 106(19): 2466 - 2472.
[Abstract] [Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
Arrhythmia Recurrence in ICD Patients: Incidence and Predictors
Journal Watch Cardiology, August 17, 2001; 2001(817): 7 - 7.
[Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement